The incidence of PCP in patients with CD4 counts <200 cells/μL, before the availability of highly active antiretroviral therapy and who were receiving PCP prophylaxis, is also demonstrated in Figure 3 (4.85events/100 PY, 95% CI 0.92–8.78) [32]–[35]. This evidence concerns the gene CD4 and pneumocystosis.